[HTML][HTML] Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients …
N Uaprasert, P Pitakkitnukun… - Blood Cancer …, 2022 - nature.com
Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study
PG Doukas, F St. Pierre, R Karmali, X Mi… - The …, 2023 - academic.oup.com
Background Chronic lymphocytic leukemia (CLL) and other non-Hodgkin's lymphomas
(NHLs) lead to broad immunosuppression, conferring a greater risk for morbidity and …
(NHLs) lead to broad immunosuppression, conferring a greater risk for morbidity and …